Transgene SA (OTCMKTS:TRGNF – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $0.78 and traded as high as $0.80. Transgene shares last traded at $0.80, with a volume of 1,600 shares trading hands.
Transgene Stock Performance
The business has a 50 day moving average of $0.78 and a 200-day moving average of $0.87.
About Transgene
Transgene is a French biotechnology company that develops immunotherapies, with a primary focus on treatments for cancer. Its research centers on therapeutic vaccines and oncolytic viruses—engineered viruses designed to target tumors and stimulate an immune response. The company’s pipeline includes candidates using viral-vector platforms, including personalized approaches intended to tailor treatment to the characteristics of an individual patient’s tumor. Transgene advances its programs through research and clinical development, often working with academic and industry partners.
Further Reading
- Five stocks we like better than Transgene
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Transgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Transgene and related companies with MarketBeat.com's FREE daily email newsletter.
